Business Wire

IMS and SES to Expand Internet Connectivity to Underserved Colombian Communities With O3b mPOWER

15.12.2021 10:50:00 EET | Business Wire | Press release

Share

SES’s satellite-based trunking services will enable leading Colombian fibre optic networks service provider Integra Multisolutions (IMS) to extend and enhance fibre-like connectivity for Colombian municipalities with fewer than 100,000 inhabitants located out of the reach of terrestrial infrastructure, SES announced today. The new service will begin on SES’s O3b medium earth orbit (MEO) constellation and later migrate onto O3b mPOWER, SES’s next-generation MEO system, in 2022 when service will expand to additional cities.

The first site to be connected will be Puerto Leguizamo, a municipality located in the Putumayo Department in the southern border region of the country. SES and IMS will go on to deliver service to other sparsely populated cities across Colombia that experience poor or inconsistent connectivity services.

SES’s Trunk mPOWERED service will equip IMS to enable local Internet service providers to serve a combination of enterprise, residential, MNO and civilian government projects. IMS is among the first companies in Latin America to sign up for the O3b mPOWER system, which can deliver low-latency, high-speed, uncontended services from tens of megabits to multiple gigabits per second to a single site.

According to the Colombian Ministry of Telecommunications, fixed broadband subscriptions in the country reached 8.22 million in 2021, which translates to 16.10 subscriptions per 100 people. However, the National Administrative and Statistics Department (Dane) revealed earlier this year the results of the Survey of Information and Communication Technologies in Households (ENTIC Hogares) showing only 56.5% of the households surveyed have an internet connection. The survey identified an important difference between households in the main cities, where 66.6% have internet access, and those in rural and dispersed areas, where only 23.9% of the households do. The Putumayo Department is among the regions with challenges to access reliable connectivity services.

“By working together with SES, we are able to quickly and cost-effectively expand our network in underserved and tough-to-reach areas helping to address the digital divide for these communities,” said Juan Carlos Hernandez Mendoza, CEO of IMS Group. “Our goal is to provide our end users the best quality of service across Colombia, which means access to high-performing services at all times, no matter where they are. The capabilities of the proven O3b MEO fleet, and the scalability and flexibility of the upcoming O3b mPOWER services combined with SES satellite network and IMS fibre optics networks expertise, allow us to achieve exactly that.”

“Our multi-orbit satellite solutions have been bringing reliable connectivity services across Colombia for almost 10 years,” said Omar Trujillo, Americas Vice President of Fixed Data Sales at SES. “We are delighted to partner with IMS to extend terrestrial networks with the revolutionary capabilities of the O3b mPOWER constellation and deliver fibre-like Internet access to Colombians wherever they live.”

Follow us on:
TwitterFacebookYouTubeLinkedInInstagram
Read our Blogs >
Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,500 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.

About IMS

IMS was created in 2016, since then IMS is becoming the main PARTNER for all the small and medium Internet Service Providers in Colombia through terrestrial telecom technologies specialized in fiber optic networks, Networking Engineering, ISP Tech Solutions, supply chain, and many more. Currently IMS has more than 100,000 kilometres of available fiber throughout Colombia and sells more than 300 Gbps of fiber optic capacity to more than 250 corporate customers, becoming a very important provider for internet carriers in the region. For more information about IMS go to www.ims.net.co.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Suzanne Ong
External Communications
+352 710 725 500
suzanne.ong@ses.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release

Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye